IDEAYA Biosciences (NASDAQ:IDYA) Price Target Cut to $45.00 by Analysts at Royal Bank Of Canada

Posted by Brenda Bartman on Nov 5th, 2026

IDEAYA Biosciences (NASDAQ:IDYA – Free Report) had its price objective trimmed by Royal Bank Of Canada from $48.00 to $45.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research firms have also recently commented on IDYA. Mizuho set a $44.00 price target on IDEAYA Biosciences in a report on Thursday, October 29th. William Blair initiated coverage on IDEAYA Biosciences in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Wedbush increased their target price on IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, October 15th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $42.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $49.91.

Check Out Our Latest Stock Analysis on IDYA

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $32.36 on Wednesday. IDEAYA Biosciences has a 1 year low of $26.81 and a 1 year high of $42.68. The firm has a fifty day moving average price of $36.71 and a 200-day moving average price of $34.03.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.04). The firm had revenue of $10.24 million during the quarter, compared to the consensus estimate of $7.58 million. IDEAYA Biosciences had a negative return on equity of 40.15% and a negative net margin of 1,157.18%. The company’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.33 EPS. As a group, equities analysts expect that IDEAYA Biosciences will post -4.52 EPS for the current year.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total transaction of $985,304.58. Following the completion of the transaction, the chief executive officer owned 690,695 shares in the company, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.70% of the company’s stock.

Institutional Trading of IDEAYA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC lifted its stake in IDEAYA Biosciences by 20.5% in the 3rd quarter. Sterling Capital Management LLC now owns 1,873 shares of the company’s stock worth $72,000 after purchasing an additional 319 shares in the last quarter. Covestor Ltd boosted its holdings in shares of IDEAYA Biosciences by 21.1% during the 3rd quarter. Covestor Ltd now owns 3,178 shares of the company’s stock valued at $122,000 after purchasing an additional 554 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of IDEAYA Biosciences by 26.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company’s stock valued at $105,000 after purchasing an additional 596 shares during the last quarter. Hsbc Holdings PLC grew its position in shares of IDEAYA Biosciences by 3.9% during the first quarter. Hsbc Holdings PLC now owns 19,258 shares of the company’s stock valued at $645,000 after purchasing an additional 725 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in shares of IDEAYA Biosciences by 6.3% during the third quarter. ProShare Advisors LLC now owns 14,740 shares of the company’s stock valued at $566,000 after purchasing an additional 876 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences News Roundup

Here are the key news stories impacting IDEAYA Biosciences this week:

Positive Sentiment: IDEAYA said it completed its NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma and highlighted encouraging data for IDE849 in relapsed small-cell lung cancer. It ended September with $1.15 billion in cash and reiterated runway into 2030, supporting development plans. Third-quarter results and business update
Positive Sentiment: Wedbush raised its price target to $63 from $60 and maintained an “outperform” rating, signaling continued confidence in the shares. Wedbush analyst ratings
Neutral Sentiment: Third-quarter revenue was $10.24 million, above estimates of about $7.6 million and up 14.6% year over year. The reported loss was $1.22 per share; analyst estimates cited in the reports ranged from a $1.18 to $1.26 loss, making the earnings comparison mixed. Third-quarter results
Neutral Sentiment: The company plans to participate in investor-relations events in November; the announcement itself did not provide a material new financial or clinical update. Investor-relations events announcement
Negative Sentiment: Royal Bank of Canada cut its target to $45 from $48 while keeping “outperform,” and Guggenheim lowered its target to $52 from $57 while retaining “buy.” The lower targets may temper sentiment, although both firms kept favorable ratings. Analyst price-target coverage

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.